TABLE 1.
Target Antigen | Primary Symptoms | Other Manifestations | Associated Tumor(s) | Demographic Data | Outcomes With Proper Therapy |
---|---|---|---|---|---|
NMDA receptor | Psychosis, seizures, autonomic instability, dyskinesias | Viral prodrome, changes in speech, catatonic features, hypoventilation | Ovarian teratoma* | 75% women; 35% children and adolescents | 75%–80% substantial improvement or full recovery |
AMPA receptor | Memory loss, confusion, agitation, seizures | Psychotic symptoms, affective changes | Breast or lung cancer, thymoma | Predominates in women, ages 50–70 | Most improve; frequent relapse |
GABAB receptor | Seizures, memory loss, confusion | Hallucinations, paranoia, odd behaviors | Small-cell lung cancer | Either gender, middle-aged | ~50% improve |
LGI1 | Amnesia, seizures, confusion, disorientation | Autonomic dysfunction, apathy/irritability, hyponatremia | Rare, thymoma | ~2:1 male: female, middle-aged | ~80% full recovery or mild deficits |
Caspr2 | Neuromyotonia, dysautonomia, confusion, insomnia | Amnesia, seizures, neuropathic pain, weight loss | Rare, thymoma | ~4:1 male: female, middle-aged | ~80% substantial improvement |
The association with teratomas is gender- and age-dependent. In women older than 18, ovarian teratomas occur in ~55% of cases. In women younger than 18, teratomas occur in 30% of cases. In women younger than 14, teratomas occur in 9% of cases. Only ~5% of men have an underlying tumor (germ-cell tumor of the testis, neuroblastoma, small-cell lung cancer).11